PLK1 and triple-negative breast carcinoma: The pharmacological inhibition of PLK1 in triple-negative breast cancer has been reported to increase the anti-proliferative activity of drug-resistant cells, which in turn causes G2/M phase block and increases the phosphorylation of cell cycle proteins inducing apoptosis74.